Ribo Life Science successfully lists on Main Board of Hong Kong Stock Exchange

This post was originally published on here

Ribo Life Science Co., a leading company in small interfering RNA (siRNA) therapeutics, has successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalisation of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry.

In its global offering, Ribo issued a total of 31,610,400 shares at an offer price of HKD 57.97 per share, raising gross proceeds of over 1.8 billion Hong Kong dollars, HKPO was over 100x oversubscribed, International Placing was 16.7x oversubscribed, reflecting strong global investor confidence in the value of the siRNA sector and the company’s capabilities.

The IPO proceeds will provide solid financial support for the advancement of the company’s core business. In addition, the offering attracted 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International and Dacheng Fund, and Taikang Life Insurance etc., demonstrating the strong confidence of leading institutions in the Company’s long-term prospects.

Proceeds from the offering will be allocated across four key areas: (1) Advancing global multicenter clinical trials for core products; (2) Supporting preclinical and clinical development of the pipeline; (3) Iterating and upgrading siRNA delivery and other technology platforms; (4) Replenishing operational capital and earmarking funds for routine corporate purposes.

Ribo has built a fully integrated R&D platform with independent intellectual property rights. Its innovative liver-targeting RiboGalSTAR^TM delivery technology has successfully advanced multiple products into Phase II clinical trials. The company has established R&D centers in Suzhou, Beijing and Gothenburg, Sweden, and a global R&D network capable of supporting end-to-end drug development from discovery to global clinical trials.